Abstract:IntroductionGliomas are the most common malignant cancer affecting the CNS, accounting for 60% of primary brain tumors (DeAngelis, 2001; Yiu&He, 2006).The majority of gliomas in adults are highly malignant with a poor prognosis, in particular with high-grade tumors such as glioblastoma multiforme.Current therapy with surgery, radiation, and chemotherapy rarely, if ever, cures the disease and infrequently prolongs life for 1 year (Curran et al., 1993;Bao et al., 2006).Additional considerations focus on developing novel modalities to increase anti-glioma effects and decrease side-effects.Differentiation therapy, using agents that modify cancer cell differentiation, has shown promise in the spectrum of agents used against tumors (Leszczyniecka et al., 2001).Wang and Chen demonstrated the clinical application for differentiation therapy by introducing all-trans-retinoic acid to clinical use for the treatment of acute promyelocytic leukemia (APL) (Huang et al., 1988; Wang&Chen, 2000).Notably, the inorganic toxicant arsenic trioxide (As2O3), a well known environmental carcinogen, has been also proven to be an effective drug in the treatment of APL patients by triggering apoptosis and differentiation of APL cells in a dose-dependent manner (Shen et al., 1997;Kinjo et al., 2000).Such excellent effects, however, were not reproduced in other hematological and, particularly, solid tumors.Differentiation agents for malignant gliomas remain a real challenge.In this chapter, we base on our research and mainly discuss proteins or molecules capable of inducing differentiation via targeting cAMP/cAMP-dependent protein kinase A (PKA) signal pathway and crucial factors such as glycogen synthase kinase-3 (GSK-3 ) and hypoxia-inducible factor-1 (HIF-1 ) determining the efficiency of these drugs.Although agents for differentiation therapy have wide application prospect, their real therapeutic potentiality remains to be further realized. The molecular mechanism for differentiation therapy of malignant glioma2.1 cAMP/PKA signaling activators induce malignant glioma cell differentiation cAMP/PKA signaling has been reported to play important roles in multiple physiological processes, including growth, differentiation, gene regulation, and apoptosis (Walsh&Van Patten, 1994).Disruption of the PKA catalytic subunit causes destabilization of the diploid cell cycle, and the cells start meiosis under conditions repressive for wild-type meiosis (Maeda et al., 1994).Ample evidences indicate that cAMP-elevating stimuli such as Nwww.intechopen.com

Disruption of β-catenin-mediated negative feedback reinforces cAMP-induced neuronal differentiation in glioma stem cells

Glioblastoma vascular plasticity limits effector T-cell infiltration and is blocked by cAMP activation.

The Molecular Mechanism for Differentiation Therapy of Malignant Glioma

Overexpression of carnitine palmitoyltransferase 1A promotes mitochondrial fusion and differentiation of glioblastoma stem cells

Differential regulation of H3K9/H3K14 acetylation by small molecules drives neuron-fate-induction of glioma cell

Autophagy impairment inhibits differentiation of glioma stem/progenitor cells.

The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype.

PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38 MAPK signalling

Glycogen Synthase Kinases-3 Beta Controls Differentiation Of Malignant Glioma Cells

Mir-221/222 Suppression Induced by Activation of the Camp/pka/creb1 Pathway is Required for Camp-Induced Bidirectional Differentiation of Glioma Cells.

Negative Regulation of Mir-1275 by H3K27me3 is Critical for Glial Induction of Glioblastoma Cells.

STEM-43. GSK3β PROMOTES THE BMX-MEDIATED STAT3 ACTIVATION TO MAINTAIN GLIOBLASTOMA STEM CELLS

GSK3β/β-catenin Signaling is Correlated with the Differentiation of Glioma Cells Induced by Wogonin

ASCL1 phosphorylation and ID2 upregulation are roadblocks to glioblastoma stem cell differentiation

ZNF117 regulates glioblastoma stem cell differentiation towards oligodendroglial lineage

Curcumin Promotes Differentiation of Glioma‐initiating Cells by Inducing Autophagy

Adenosine 3':5'-Cyclic Monophosphate Induces Differentiation of Glioma Cells : an Experimental Study

Induction Of Autophagy Promotes Differentiation Of Glioma-Initiating Cells And Their Radiosensitivity

MicroRNA 335 is required for differentiation of malignant glioma cells induced by activation of cAMP/protein kinase A pathway.

Molecular Pathways and Genomic Landscape of Glioblastoma Stem Cells: Opportunities for Targeted Therapy

CNSC-12. NEURONAL DIFFERENTIATION DRIVES THE ANTI-TUMOR EFFICACY OF MEK INHIBITION IN GLIOBLASTOMA